Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

SELL
$0.9 - $1.83 $189 - $384
-210 Reduced 0.55%
37,861 $46,000
Q4 2023

Feb 07, 2024

BUY
$0.42 - $0.57 $44 - $60
107 Added 0.28%
38,071 $21,000
Q1 2023

May 15, 2023

BUY
$0.64 - $3.15 $24,296 - $119,586
37,964 New
37,964 $27,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $174M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Us Asset Management LLC Portfolio

Follow Us Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Us Asset Management LLC with notifications on news.